ASXL1 and leukemia: Moreover, while some studies have identified that subclonal nondriver mutations (i.e., ASXL1, EZH2, IDH1/2, and SRSF2) have an adverse effect on overall and leukemia-free survival [10, 11], and therefore may be used as a decisional tool for transplant (MIPPS70 [12]), this kind of analysis was not available in clinical practice in 2013, and the only information about the mutational status of our patient was the negativity for JAK2 V617F.